Cardioprotective actions of nitroxyl donor Angeli's salt are preserved in the diabetic heart and vasculature in the face of nitric oxide resistance. (26th April 2022)
- Record Type:
- Journal Article
- Title:
- Cardioprotective actions of nitroxyl donor Angeli's salt are preserved in the diabetic heart and vasculature in the face of nitric oxide resistance. (26th April 2022)
- Main Title:
- Cardioprotective actions of nitroxyl donor Angeli's salt are preserved in the diabetic heart and vasculature in the face of nitric oxide resistance
- Authors:
- Velagic, Anida
Li, Jasmin Chendi
Qin, Cheng Xue
Li, Mandy
Deo, Minh
Marshall, Sarah A.
Anderson, Dovile
Woodman, Owen L.
Horowitz, John D.
Kemp‐Harper, Barbara K.
Ritchie, Rebecca H. - Abstract:
- Abstract : Background and Purpose: The risk of fatal cardiovascular events is increased in patients with type 2 diabetes mellitus (T2DM). A major contributor to poor prognosis is impaired nitric oxide (NO) signalling at the level of tissue responsiveness, termed NO resistance. This study aimed to determine if T2DM promotes NO resistance in the heart and vasculature and whether tissue responsiveness to nitroxyl (HNO) is affected. Experimental Approach: At 8 weeks of age, male Sprague–Dawley rats commenced a high‐fat diet. After 2 weeks, the rats received low‐dose streptozotocin (two intraperitoneal injections, 35 mg·kg −1, over two consecutive days) and continued on the same diet. Twelve weeks later, isolated hearts were Langendorff‐perfused to assess responses to the NO donor diethylamine NONOate (DEA/NO) and the HNO donor Angeli's salt. Isolated mesenteric arteries were utilised to measure vascular responsiveness to the NO donors sodium nitroprusside (SNP) and DEA/NO, and the HNO donor Angeli's salt. Key Results: Inotropic, lusitropic and coronary vasodilator responses to DEA/NO were impaired in T2DM hearts, whereas responses to Angeli's salt were preserved or enhanced. Vasorelaxation to Angeli's salt was augmented in T2DM mesenteric arteries, which were hyporesponsive to the relaxant effects of SNP and DEA/NO. Conclusion and Implications: This is the first evidence that inotropic and lusitropic responses are preserved, and NO resistance in the coronary and mesentericAbstract : Background and Purpose: The risk of fatal cardiovascular events is increased in patients with type 2 diabetes mellitus (T2DM). A major contributor to poor prognosis is impaired nitric oxide (NO) signalling at the level of tissue responsiveness, termed NO resistance. This study aimed to determine if T2DM promotes NO resistance in the heart and vasculature and whether tissue responsiveness to nitroxyl (HNO) is affected. Experimental Approach: At 8 weeks of age, male Sprague–Dawley rats commenced a high‐fat diet. After 2 weeks, the rats received low‐dose streptozotocin (two intraperitoneal injections, 35 mg·kg −1, over two consecutive days) and continued on the same diet. Twelve weeks later, isolated hearts were Langendorff‐perfused to assess responses to the NO donor diethylamine NONOate (DEA/NO) and the HNO donor Angeli's salt. Isolated mesenteric arteries were utilised to measure vascular responsiveness to the NO donors sodium nitroprusside (SNP) and DEA/NO, and the HNO donor Angeli's salt. Key Results: Inotropic, lusitropic and coronary vasodilator responses to DEA/NO were impaired in T2DM hearts, whereas responses to Angeli's salt were preserved or enhanced. Vasorelaxation to Angeli's salt was augmented in T2DM mesenteric arteries, which were hyporesponsive to the relaxant effects of SNP and DEA/NO. Conclusion and Implications: This is the first evidence that inotropic and lusitropic responses are preserved, and NO resistance in the coronary and mesenteric vasculature is circumvented, by the HNO donor Angeli's salt in T2DM. These findings highlight the cardiovascular therapeutic potential of HNO donors, especially in emergencies such as acute ischaemia or heart failure. Abstract : … (more)
- Is Part Of:
- British journal of pharmacology. Volume 179:Number 16(2022)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 179:Number 16(2022)
- Issue Display:
- Volume 179, Issue 16 (2022)
- Year:
- 2022
- Volume:
- 179
- Issue:
- 16
- Issue Sort Value:
- 2022-0179-0016-0000
- Page Start:
- 4117
- Page End:
- 4135
- Publication Date:
- 2022-04-26
- Subjects:
- cardiovascular disease -- diabetes -- HNO -- nitric oxide resistance -- nitroxyl -- type 2 diabetes
Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/bph.15849 ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 22602.xml